for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
PharmAsia News
   Full-text available via subscription Subscription journal
     ISSN (Print) 1875-7774
     Published by Informa plc Homepage  [13 journals]
  • PHARMAC Stressing Biosimilar Use For Savings
    • Abstract: In its annual review, the New Zealand pharmaceutical management agency PHARMAC says it has made substantial savings from switching to generics and is also now emphasizing the use of biosimilars.
      PubDate: Fri, 19 Dec 2014 03:40:01 -050
  • Novartis Submits More Info On Japan Diovan, Side-Effects Affair
    • Abstract: Novartis's Japanese subsidiary has submitted further findings from investigations into the company’s involvement in physician-led clinical research and delays in reporting adverse events.
      PubDate: Fri, 19 Dec 2014 03:30:01 -050
  • SciClone Signs MedCo To Fill CV Warchest In China
    • Abstract: It’s a Santa Surprise for SciClone with two cardiovascular agent additions from The Medicines Co. after the termination of a Sanofi promotion agreement a year ago. China’s lengthy and unpredictable regulatory process, however, could cast a shadow over the cheerful prospects.
      PubDate: Fri, 19 Dec 2014 03:05:01 -050
  • Indian Industry Vows To Tackle Pharma Quality Woes
    • Abstract: Drug company executives and senior civil servants in India want to make a strong push to regain trust in pharmaceutical manufacturing, vowing to make needed changes quickly at a conclave in New Delhi.
      PubDate: Thu, 18 Dec 2014 19:25:00 -050
  • China Medtech Joint Ventures – Ordeal Or Adventure' Part 2
    • Abstract: An increasing number of SMEs are going down the joint venture route to establish a presence in the sizeable Chinese healthcare market. In this second instalment of a two-part feature, Tina Tan asks Enigma Diagnostics CEO John McKinley about his experiences of finding the right partner for a joint venture in China.
      PubDate: Thu, 18 Dec 2014 18:00:06 -050
  • Emerging Markets Regulatory Tracker: India (Vol. 4 No. 79)
    • Abstract: India’s CDSCO issues final rules for non-fatal injuries in clinical trials, amending the formula for determining compensation.
      PubDate: Wed, 17 Dec 2014 23:55:01 -050
  • Hengrui Launches Apatinib With Echoes Of Icotinib Approach
    • Abstract: Jiangsu Hengrui is going all out for its apatinib launch, combining a follow-on study and patient assistance with post-marketing research and local reimbursement talks. Will the comprehensive strategy work for the gastric cancer drug like it has for Betta in the lung cancer market?
      PubDate: Wed, 17 Dec 2014 20:35:00 -050
  • FDA Generics Office Hopes To Clear Unmeasured ANDAs
    • Abstract: The U.S. FDA’s Office of Generic Drugs restructures again and adds specialist who helped relieve supplement backlog to improve ANDA review process.
      PubDate: Wed, 17 Dec 2014 19:30:01 -050
  • Australia’s Universal Biosensors Leaps Into Europe With Xprecia
    • Abstract: Australia device and diagnostics firm Universal Biosensors inks a deal with Siemens Healthcare to bring its Xprecia Stride coagulation analyzer into Europe, perking up its share price and outlook.
      PubDate: Wed, 17 Dec 2014 19:20:01 -050
  • Fruquintinib Phase III Start Marks More China Innovation
    • Abstract: Hutchison MediPharma (HMP) has initiated a pivotal Phase III trial program in China with its most advanced pipeline oncology project, fruquintinib.
      PubDate: Wed, 17 Dec 2014 04:15:03 -050
  • India Talks Up Regulatory Revamp
    • Abstract: Under serious pressure, the Indian health ministry has laid out a plan to modernize the regulatory system at both the central and state level.
      PubDate: Tue, 16 Dec 2014 17:35:01 -050
  • China Medtech Joint Ventures – Ordeal Or Adventure' Part 1
    • Abstract: Setting up a joint venture with a Chinese partner offers one access route. In the first of a two-part feature looking at companies’ experiences breaking into China, Clinica’s Tina Tan speaks to Raymond Akers, executive chairman of Akers Biosciences, to learn about his journey to signing a deal with a Chinese JV partner and the challenges he faced.
      PubDate: Tue, 16 Dec 2014 17:30:04 -050
  • ICH Reforms Could Strengthen Harmonization Process
    • Abstract: A 25-year-old organization where top rule-makers and industry groups reach agreement on pharmaceutical quality guidelines will incorporate next year in Switzerland. The new association could strengthen the role of emerging market authorities in global regulatory harmonization – at least those that meet its membership criteria.
      PubDate: Tue, 16 Dec 2014 17:30:00 -050
  • Is UCB Scaling Back Its Indian Business'
    • Abstract: Belgian drug maker UCB is said to be facing various headwinds in India. It is therefore reducing its exposure marking a big change from what it had at once described as a strategic emerging market.
      PubDate: Tue, 16 Dec 2014 03:55:01 -050
  • Blopress Under Attack In Japan Generic Listing
    • Abstract: Japan has listed in the national insurance reimbursement tariff its latest batch of generic drugs, awarding prices to 521 products from 72 companies, including versions of Takeda's blockbuster antihypertensive Blopress.
      PubDate: Tue, 16 Dec 2014 03:40:01 -050
  • New Data Look Positive For Otsuka/Lundbeck’s Brexpiprazole
    • Abstract: Otsuka and Lundbeck have released new Phase III clinical data for their strategically important pipeline drug brexpiprazole, showing positive results in both schizophrenia and major depression from trial programs being used to support a U.S. approval.
      PubDate: Tue, 16 Dec 2014 00:01:01 -050
  • Asia At Center Of Type 2 Diabetes Storm
    • Abstract: India and China remain at the center of a diabetes storm in Asia with type 2 cases showing up among a younger population at a faster pace than Western counterparts. International diabetes expert Gregory Fulcher sat down with PharmAsia News on the sidelines of the 10th International Diabetes Federation-Western Pacific Region held jointly with the 6th Asian Association for the Study of Diabetes Meeting in Singapore in November and discussed the outlook for treatment and diagnostics.
      PubDate: Mon, 15 Dec 2014 17:35:09 -050
  • Roundup: Five China Regulatory Must-Reads From 2014
    • Abstract: Change, turmoil and transition mark the passing Year of the Horse for the China pharma industry. If you have missed some of the highlights, here is your opportunity to check out the top China drug regulatory happenings in 2014.
      PubDate: Mon, 15 Dec 2014 17:35:02 -050
  • Top Digital Marketing Trends In Emerging Markets
    • Abstract: Pharmaceutical marketers in China, Japan and certain emerging markets are experimenting rather seriously with digital channels for engagement with healthcare professionals, with up to a quarter of marketing budgets allocated for digital spends by those ahead of the curve, according to a new study by Indegene.
      PubDate: Mon, 15 Dec 2014 00:30:01 -050
  • Parallel Trade Dogs Turkey’s Pharma Import Efforts
    • Abstract: While looking at eliminating the Union of Turkish Pharmacists’ monopoly on importing drugs for individual patients, the government has run up against the problem of parallel trade. Companies newly licensed for drug imports are reselling products to other countries (mainly in Europe), and since Turkey has some of the lowest drug prices in Europe, the difference can generate high revenues.
      PubDate: Sun, 14 Dec 2014 17:30:00 -050
  • Pentavalent Product Another Feather In Indonesia’s Vaccines Cap
    • Abstract: The roll out of Bio Farma's pentavalent pediatric vaccine across Indonesia this year marks another triumph for the country's indigenous vaccines industry, which has achieved self-sufficiency in essential vaccines and is now positioning itself as a leader in the Muslim world.
      PubDate: Sun, 14 Dec 2014 17:25:02 -050
  • Generics REMS Hurdles Lowered Somewhat By FDA Protocol Letters
    • Abstract: But the U.S. FDA still cannot force brand firms to provide products for bioequivalence testing, which may limit the policy’s ability to remove a barrier that generic firms allege some NDA sponsors use to block competition.
      PubDate: Sun, 14 Dec 2014 17:20:02 -050
  • Finally, Novartis Takes Cipla To Court Over Onbrez Patents
    • Abstract: A new legal battle between Cipla and Novartis related to product patents for respiratory drug Onbrez is set to unfold in India. Both sides are expected to claim strongly that they are filling the needs of patients for affordable and innovative drugs.
      PubDate: Fri, 12 Dec 2014 06:00:00 -050
  • Bayer Facing China Challenges In Growth Push
    • Abstract: Bayer hopes to drive healthcare sales growth through 2016 despite regulatory headwinds in China, one of the German multinational's most important emerging markets.
      PubDate: Fri, 12 Dec 2014 00:40:00 -050
  • Australia Biotech Conference: Winning China Biotech Partnerships
    • Abstract: With the Australia-China Free Trade Agreement negotiations competed and scheduled to be finalized in 2015, growing opportunities exist for Australian biotech and life science companies to develop deals with Chinese partners. A panel of China specialists in legal, pharma, investment and health sciences discussed how to build winning biotech deals in China at the Australia Biotech Invest Conference in Melbourne on Dec.3 and 4.
      PubDate: Thu, 11 Dec 2014 23:45:01 -050
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014